Comparative pharmacokinetic profiling of different polymyxin B components

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 11, 2016, Pages 6980-6982

  Manchandani, Pooja ^a   Dubrovskaya, Yanina ^b   Gao, Song ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B; ANTIINFECTIVE AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CASE REPORT; COMPARATIVE STUDY; DRUG BLOOD LEVEL; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MALE; MIDDLE AGED; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; CHEMISTRY; GRAM-NEGATIVE BACTERIAL INFECTIONS; SPRAGUE DAWLEY RAT;

AGED; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLYMYXIN B; RATS, SPRAGUE-DAWLEY;

EID: 84994499985     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00702-16     Document Type: Article

References (9)

1. Curcio D. 2014. Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge? Curr Clin Pharmacol 9:27-38. http://dx.doi.org/10.2174/15748847113089990062.
2. Vergidis PI, Falagas ME. 2008. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr Opin Investig Drugs 9:176-183.
3. Orwa JA, Govaerts C, Busson R, Roets E, Van Schepdael A, Hoogmartens J. 2001. Isolation and structural characterization of polymyxin B components. J Chromatogr A 912:369-373. http://dx.doi.org/10.1016/S0021-9673(01)00585-4.
4. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. 2012. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 56:5724-5727. http://dx.doi.org/10.1128/AAC.01333-12.
5. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
6. Tam VH, Cao H, Ledesma KR, Hu M. 2011. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother 55:4490-4491. http://dx.doi.org/10.1128/AAC.00119-11.
7. Tam VH, Hou J, Kwa AL, Prince RA. 2009. Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother 63:627-629. http://dx.doi.org/10.1093/jac/dkn483.
8. He J, Gao S, Hu M, Chow DS, Tam VH. 2013. A validated ultraperformance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 68:1104-1110. http://dx.doi.org/10.1093/jac/dks536.
9. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:3624-3630. http://dx.doi.org/10.1128/AAC.49.9.3624-3630.2005.